COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,282 Articles (22,759 medRxiv, 8,523 bioRxiv)

Most recent first Previous |  Page 1345: Articles 13441-13450  | Next

Safety and efficacy of COVID-19 hyperimmune globulin (HIG) solution in the treatment of active COVID-19 infection- Findings from a Prospective, Randomized, Controlled, Multi-Centric Trial
Parikh, D., Chaturvedi, A., Shah, N., Patel, P., Patel, R., Ray, S.
10.1101/2021.07.26.21261119 — Posted: 2021-07-27
Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis
Singer, M. E., Taub, I. B., Kaelber, D. C.
10.1101/2021.07.23.21260998 — Posted: 2021-07-27 Discussion: Onsite
Vaccines against Covid-19, venous thromboembolism, and thrombocytopenia. A population-based retrospective cohort study
Laporte, J.-R., Coma, E., Fina, F., Garcia-Eroles, L., Vidal, X., Medina, M.
10.1101/2021.07.23.21261036 — Posted: 2021-07-27 Discussion: Onsite
The Costs and Benefits of Covid-19 Lockdowns in New Zealand
Lally, M.
10.1101/2021.07.15.21260606 — Posted: 2021-07-27
CIGB-300 synthetic peptide, an antagonist of CK2 kinase activity, as a treatment for Covid-19. A computational biology approach
Miranda, J., Bringas, R., de-Cossio, J. F., Perera, Y.
10.1101/2021.07.26.453805 — Posted: 2021-07-26
Can we clinically identify pre-symptomatic and asymptomatic COVID-19?
Elhamamsy, S., Devone, F., Bayer, T., Halladay, C., Cadieux, M., McConeghy, K., Rajan, A., Sachar, M., Mujahid, N., Nanda, A., McNicoll, L., Rudolph, J., Gravenstein, S.
10.1101/2021.07.23.21260676 — Posted: 2021-07-26
Protection of human ACE2 transgenic Syrian hamsters from SARS CoV-2 variants by human polyclonal IgG from hyper-immunized transchromosomic bovines
Gilliland, T., Liu, Y., Li, R., Dunn, M., Cottle, E., Terada, Y., Ryckman, Z., Alcorn, M., Vasilatos, S., Lundy, J. D., Larson, D., Wu, H., Luke, T., Bausch, C., Egland, K., Sullivan, E., Wang, Z., Klimstra, W.
10.1101/2021.07.26.453840 — Posted: 2021-07-26
ETAS(R)50 Attenuates SARS-CoV-2 Spike Protein-Induced IL-6 and IL-1β Production by Suppressing p44/42 MAPK and Akt Phosphorylation in Murine Primary Macrophages
Shirato, K., Takanari, J., Kizaki, T.
10.1101/2021.07.25.453717 — Posted: 2021-07-26 Discussion: Onsite
Increased aerosol transmission for B.1.1.7 (alpha variant) over lineage A variant of SARS-CoV-2
Port, J., Yinda, K. C., Avanzato, V., Schulz, J., Holbrook, M., van Doremalen, N., Shaia, C., Fischer, R., Munster, V.
10.1101/2021.07.26.453518 — Posted: 2021-07-26
Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralising SARS-CoV-2 nanobodies
Hanke, L., Sheward, D. J., Pankow, A., Perez Vidakovics, L., Karl, V., Kim, C., Urgard, E., Smith, N. L., Astorga-Wells, J., Ekström, S., Coquet, J. M., McInerney, G. M., Murrell, B.
10.1101/2021.07.25.453673 — Posted: 2021-07-26

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).